Joel S. Marcus, Director at Intra-Cellular Therapies, Inc. (ITCI), sold 5,000 shares at $50.82 ($254K) on 2022-12-19, disclosed to the SEC on 2022-12-21.
Open-market sale of $254k ITCI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| ARE | BUY | 2026-05-07 | $348K | — | Filing → |
| ARE | BUY | 2026-05-06 | $320K | — | Filing → |
| ARE | BUY | 2026-05-05 | $410K | — | Filing → |